Quote: The challenges of antitrust enforcement in health care

The complexity of this undertaking highlights a fundamental enforcement reality. If it’s this hard for regulators to demonstrate why a patently worrisome acquisition should be blocked, it is even less likely that they will investigate or attempt to halt mergers for which potential effects are unclear. […]

Consolidation will surely continue before we can determine whether it is benign.

Leemore Dafny, The New England Journal of Medicine


Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on email

Hidden information below


* indicates required
Email Format